What is a clinical trial?

Clinical trials are research studies designed to evaluate experimental treatments and procedures. Most breakthroughs in the diagnosis, treatment, and care of patients with cancer exist because of clinical trials.

Clinical trials have specific treatment plans with specific eligibility criteria. Criteria differ from study to study, and are frequently based on age, sex, type/stage of cancer, medical history, and current health status. Participation in a trial requires the ability to travel to the clinical trial center (in this case, the Saint John’s Cancer Institute).

Search for Open Clinical Trials at Saint John’s Cancer Institute.

What is it like to participate in a clinical trial?

Mark Perzley is interviewed by Saint John’s Cancer Institute in Santa Monica, California.

Saint John’s Experts Explain the Importance of Clinical Trials

Doctors, Kim Margolin, Santosh Kesari, Przemyslaw Twardowski, Parvin Peddi, Leland Foshag, and Emma Chacon deep dive into clinical trials and their significance to their patients and others.

Have questions?

For more information about any of our clinical trials, or general questions, please call our main hotline.   See Clinical Trials FAQs for additional information.

The clinical trials listed below represent active and enrolling trials. We implement, initiate, and oversee clinical trials here, at Saint John’s Cancer Institute, as well as other facilities in the Southern California region.

Search using key terms or filter by Centers of Excellence or by Lead Doctor.

Title Center Name Physician

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT ID : 05894239
Protocol Number : WO44263
Phase : 3
Location : Burbank, California

Breast Surgery and Oncology

Erwin Grussie, MD

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50%

NCT ID : 06170788
Protocol Number : MK2870-007
Phase : 3
Location : Burbank, California

Thoracic

Karlton Wong, MD

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial

NCT ID : 05554380
Protocol Number : EAY191-S3
Phase : 2
Location : Santa Monica, CA

Multiple Tumors

Revo Basho, M.D.

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial

NCT ID : 05554354
Protocol Number : EAY191-N2
Phase : 2
Location : Santa Monica, CA

Breast Surgery and Oncology

Revo Basho, M.D.

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT ID : 05564377
Protocol Number : EAY191
Phase : 2
Location : Santa Monica, CA

Breast Surgery and Oncology

Gynecologic Oncology

Revo Basho, M.D.

Testing the Role of FDG-PET/​CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT ID : 05710328
Protocol Number : EA1211
Phase : 2
Location : Santa Monica, Ca

Breast Surgery and Oncology

Parvin Peddi, M.D.

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

NCT ID : 05529316
Protocol Number : C-800-23
Phase : 2
Location : Santa Monica, Ca

Melanoma, Skin and Soft Tissue Tumors

Kim Margolin, M.D.

Safety and Efficacy Study of NUV-868 Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

NCT ID : 05252390
Protocol Number : NUV-868-01
Phase : 1/2
Location : Santa Monica, Ca

Urology and Urologic Oncology

Mitchell Gross, M.D.

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT ID : 05608291
Protocol Number : R3767-ONC-2055
Phase : 3
Location : Saint John's Cancer Institute

Melanoma, Skin and Soft Tissue Tumors

Kim Margolin, M.D.

A Beta-only IL-2 Immunotherapy Study (ABILITY-1)

NCT ID : 05086692
Protocol Number : MDNA 11-01
Phase : 1/2
Location : Saint John's Cancer Institute

All Solid Tumors

Przemyslaw Twardowski, M.D.

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

NCT ID : 04658862
Protocol Number : 17000139BLC3001 (Sunshine 2)
Phase : 3
Location : Saint John's Cancer Institute

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

A Study of ARV-766 Given by Mouth in Men With Metastatic Castration-resistant Prostate Cancer Who Have Progressed on Prior Approved Systemic Therapies

NCT ID : 05067140
Protocol Number : ARV-766mCRPC-101
Phase : 1/2
Location : Saint John's Cancer Institute

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

NCT ID : 03972657
Protocol Number : R5678-ONC-1879
Phase : 1/2
Location : Saint John's Cancer Institute

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT ID : 05812807
Protocol Number : A012103
Phase : 3
Location : Saint John's Cancer Institute

Breast Surgery and Oncology

Parvin Peddi, M.D.

(SPARTA) APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT ID : 03175224
Protocol Number : SPARTA APL-101
Phase : 2
Location : Saint John's Cancer Institute

All Solid Tumors

Akanksha Sharma, M.D.

A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)

NCT ID : 05155332
Protocol Number : 1456-0001
Phase : 1
Location : Saint John's Cancer Institute

All Solid Tumors

Naveed Wagle, M.D.

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION)

NCT ID : 05580562
Protocol Number : ONC201-108
Phase : 3
Location : Saint John's Cancer Institute

Brain Tumors & Neuroscience

Akanksha Sharma, M.D.

Known Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions

NCT ID : 05068726
Protocol Number : GE-280-401
Phase : 4
Location : Saint John's Cancer Institute

Breast Surgery and Oncology

Parvin Peddi, M.D.

Metastatic Castration-Resistant Prostate Cancer (CAPItello-280)

NCT ID : 05348577
Protocol Number : D361EC00001 (CAPItello-280)
Phase : 3
Location : Santa Monica, Ca

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

Locally advanced or metastatic solid tumors: A Phase I Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects with Advanced Cancer

NCT ID : 03860272
Protocol Number : C-800-01
Phase : 1
Location : Santa Monica, CA

All Solid Tumors

Multiple Tumors

Kim Margolin, M.D.

Melanoma, Merkel Cell, Renal Cell NSCLC (iPREDICT)

NCT ID : 05013099
Protocol Number : IAB-CD8-203
Phase : 2b
Location : Santa Monica, CA

All Solid Tumors

Kim Margolin, M.D.

Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT.

NCT ID : 03488693
Protocol Number : CCTGMA.39
Phase : 3
Location : Santa Monica, CA

Breast Surgery and Oncology

Janie Grumley, M.D.

All Solid Metastatic or Advanced Tumors: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

NCT ID : 04246671
Protocol Number : TAEK-VAC-HerBy-001
Phase : 1
Location : Saint John's Cancer Institute

All Solid Tumors

Naveed Wagle, M.D.

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (WHO Grade IV)

NCT ID : 04762069
Protocol Number : CNS-201
Phase : 2
Location : Saint John's Cancer Institute

Brain Tumors & Neuroscience

Naveed Wagle, M.D.

Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT ID : 04958785
Protocol Number : GS-US-586-6144
Phase : 2
Location : Saint John's Cancer Institute

Breast Surgery and Oncology

Parvin Peddi, M.D.

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

NCT ID : 05568472
Protocol Number : SWOG-S2010
Phase : 3
Location : Saint John's Cancer Institute

Breast Surgery and Oncology

Janie Grumley, M.D.

White Button Mushroom Supplement for Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Naïve Patients 

NCT ID : 04519879
Protocol Number : White Button Mushroom
Phase : 2
Location : Santa Monica, CA

Urology and Urologic Oncology

Przemyslaw Twardowski, M.D.

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

NCT ID : 04566393
Protocol Number : ULI-EAP-100
Phase : N/A
Location : Santa Monica, CA

Multiple Tumors

Naveed Wagle, M.D.

Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas

NCT ID : 04617002
Protocol Number : ONC028
Phase : N/A
Location : Santa Monica, CA

Brain Tumors & Neuroscience

Akanksha Sharma, M.D.

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma

NCT ID : 04388475
Protocol Number : OKN-007-OL
Phase : 1
Location : Saint John's Cancer Institute

Brain Tumors & Neuroscience

Naveed Wagle, M.D.

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

NCT ID : N/A
Protocol Number : CBI_2019_SLNBprosp_001
Phase : N/A
Location : Santa Monica, CA

Melanoma, Skin and Soft Tissue Tumors

Richard Essner, M.D.

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

NCT ID : 04873362
Protocol Number : WO42633
Phase : 3
Location : Disney Family Cancer Center

Breast Surgery and Oncology

Erwin Grussie, M.D.